Professor Lee Ji-yeol as the new head of Catholic University's Seoul St. Mary's Hospital
Aug 29, 2025
Professor Lee Ji-yeol (60) of the Department of Urology was appointed as the director of the 25th hospital of the Catholic University of Korea's Seoul St. Mary's Hospital. The term of office is two years from September 1, 2025 to August 31, 2027.
Lee graduated from Catholic Medical School in 1989 and received a master's and doctorate degrees from the same graduate school. He is an authority in the field of urological cancer and a urologist who has been trying to provide customized treatment for each patient and find the best treatment using advanced information and communication technology.
He was the first head of the smart hospital, the head of the robotic surgery center, and the clinical director of the urology department at Seoul St. Mary's Hospital, and at Catholic Medical School, he served as the head of the Catholic Cancer Research Institute and the head of the Central Bank of Human Derivatives at the Medical Life Industry Research Institute. Major academic activities include the President of the Urological Society of Basic Medicine, the President of the Korean Prostate Society, the President of the Asia-Pacific Prostate Society, and the President of the Asia-Pacific Clinical Genomics Society. Currently, he continues to be active as the head of the Catholic Front Research Institute on the floor and the president of the Asia-Pacific Urological Oncology Society at the conference.
The head of the hospital also achieved 2,000 robotic surgeries last year. He is also known by his reputation as he has continued sophisticated surgery since the early days of robotic surgery in the field of urological cancer. As a result, it has continued to develop high-level cancer surgery such as prostate cancer, kidney cancer, and bladder cancer and minimally invasive surgery for various urinary diseases, taking the lead in improving the quality of life after surgery as well as treating patients.
In addition to robotic surgery, it has also provided the best treatment to patients by integrating several latest treatment options. For the first time in Korea, metastatic prostate cancer patients who do not respond to anticancer drugs have been treated with lutexium (Lu-177), which targets cancer cells using radioactive isotopes. On the other hand, for local prostate cancer, nanoknife treatment is the only one in Korea that removes cancer cells using an electric field.
In order to lay the foundation for clinical research, the first Asian sample bank for prostate disease (Biobank) was established since 2006. Expecting that prostate diseases will increase as Korea enters an aging society, it has continued to study the characteristics and genes of prostate cancer in Korea by collecting tissues, genes, and blood of prostate cancer patients to prevent and effectively treat prostate diseases. As a result, it maintained active cooperative relationships with foreign institutions such as the United States, Japan, and Singapore as well as Korea and published research results in international academic journals.
For the development of the latest treatment for urological cancer and the development of robotic surgery technology, he has published research papers in a number of domestic and foreign journals and actively participated in international conferences, and has been doing his best to cultivate talents who will lead the future of urology by running education and mentoring programs for junior doctors.
It established a smart hospital to increase patient convenience and improve treatment effect by applying IT and artificial intelligence technologies to medical care, and served as the first head of a smart hospital. It has also developed a 'Smart Follow-up Management' application that helps patients who have undergone surgery recover quickly by applying smart devices and applied it to patients not only in Korea but also abroad.
Meanwhile, the inauguration ceremony will be held at 4 p.m. on September 11 at the auditorium on the basement floor of the main building of Seoul St. Mary's Hospital.
Lee graduated from Catholic Medical School in 1989 and received a master's and doctorate degrees from the same graduate school. He is an authority in the field of urological cancer and a urologist who has been trying to provide customized treatment for each patient and find the best treatment using advanced information and communication technology.
He was the first head of the smart hospital, the head of the robotic surgery center, and the clinical director of the urology department at Seoul St. Mary's Hospital, and at Catholic Medical School, he served as the head of the Catholic Cancer Research Institute and the head of the Central Bank of Human Derivatives at the Medical Life Industry Research Institute. Major academic activities include the President of the Urological Society of Basic Medicine, the President of the Korean Prostate Society, the President of the Asia-Pacific Prostate Society, and the President of the Asia-Pacific Clinical Genomics Society. Currently, he continues to be active as the head of the Catholic Front Research Institute on the floor and the president of the Asia-Pacific Urological Oncology Society at the conference.
The head of the hospital also achieved 2,000 robotic surgeries last year. He is also known by his reputation as he has continued sophisticated surgery since the early days of robotic surgery in the field of urological cancer. As a result, it has continued to develop high-level cancer surgery such as prostate cancer, kidney cancer, and bladder cancer and minimally invasive surgery for various urinary diseases, taking the lead in improving the quality of life after surgery as well as treating patients.
In addition to robotic surgery, it has also provided the best treatment to patients by integrating several latest treatment options. For the first time in Korea, metastatic prostate cancer patients who do not respond to anticancer drugs have been treated with lutexium (Lu-177), which targets cancer cells using radioactive isotopes. On the other hand, for local prostate cancer, nanoknife treatment is the only one in Korea that removes cancer cells using an electric field.
In order to lay the foundation for clinical research, the first Asian sample bank for prostate disease (Biobank) was established since 2006. Expecting that prostate diseases will increase as Korea enters an aging society, it has continued to study the characteristics and genes of prostate cancer in Korea by collecting tissues, genes, and blood of prostate cancer patients to prevent and effectively treat prostate diseases. As a result, it maintained active cooperative relationships with foreign institutions such as the United States, Japan, and Singapore as well as Korea and published research results in international academic journals.
For the development of the latest treatment for urological cancer and the development of robotic surgery technology, he has published research papers in a number of domestic and foreign journals and actively participated in international conferences, and has been doing his best to cultivate talents who will lead the future of urology by running education and mentoring programs for junior doctors.
It established a smart hospital to increase patient convenience and improve treatment effect by applying IT and artificial intelligence technologies to medical care, and served as the first head of a smart hospital. It has also developed a 'Smart Follow-up Management' application that helps patients who have undergone surgery recover quickly by applying smart devices and applied it to patients not only in Korea but also abroad.
Meanwhile, the inauguration ceremony will be held at 4 p.m. on September 11 at the auditorium on the basement floor of the main building of Seoul St. Mary's Hospital.
|
This article was translated by Naver AI translator.
